pembrolizumab
merck
['pembro']
no new safety signals including in subset with 2y of pembrolizumab therapy. reaffirms soc and refreshing to see long term benefit in subset of patients. efforts now focusing on identifying who those patients are and how we can provide that benefit to more / all patients! #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him